Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02179060
Other study ID # R14025
Secondary ID
Status Terminated
Phase
First received June 2, 2014
Last updated March 19, 2018
Start date June 2014
Est. completion date April 1, 2016

Study information

Verified date March 2018
Source Tampere University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Therapeutic hypothermia improves the neurologically-intact survival rates in those patients resuscitated out-of-hospital from ventricular fibrillation. Cooling as early as possible might be beneficial to those victims. Diffusion Tensor Imaging and diffusion-weighted magnetic resonance imaging have recently shown to be able to identify early ischemia-related changes within the brain three days after cardiac arrest, among sudden cardiac arrest patients cooled in hospital. The physical changes seen within the brain may be able to distinguish survivors at very early phase.

This study aims to assess early ischemia-related changes of the brain seen in MRI approximately three days after cardiac arrest. The hypotheses is that MRI will differ in the groups of patients treated with early intra-arrest cooling with the RhinoChill device and in hospital hypothermia in 36 Celsius, in the group of patients treated with normal in hospital hypothermia in 36 Celsius only, in the group of patients treated with normal in hospital hypothermia in 33 Celsius only (The historical Xenon study patients). The primary endpoint is the presence and pattern of white matter and gray matter degeneration and volumetric changes of the gray matter, white matter, and cerebro-spinal fluid spaces in MRI, and secondary endpoints are total survival at 90 days, and time to reach a target temperature (≤36/33 Celsius).


Description:

Medical personnel (e.g,. nurses or physicians) responding to a cardiac arrest will assess each patient for study inclusion. During resuscitation patients will receive standard ALS (advanced life support) according to European Resuscitation Council (ERC) guidelines with cooling with the RhinoChill upon determining that the patient is in cardiac arrest. The RhinoChill catheters should be placed and cooling initiated immediately after airway management (i.e. laryngeal mask or intubation). The aim is that cooling should be started within 15 minutes from the call to the dispatch centre. Specifically, cooling with chilled saline or cold packs in the field or ambulance will not be permitted. Resuscitation attempts should be continued for at least 45 minutes after the collapse in all patients having venticular fibrillation (VF) or non-perfusive venticular tachycardia (VT) as initial cardiac rhythm before deciding that further interventions are futile.

Automated external defibrillator (AEDs) with the capability to record data will be used in each resuscitation attempt, and the quality of cardio pulmonary resuscitation (CPR) is followed.

RhinoChill cooling will be continued in those subjects that achieve ROSC and remain comatose. Bolus doses of sedation and analgesia will be administered for their transport to the hospital according to local protocol. RhinoChill cooling will be continued at the hospital until the subject can be successfully transitioned to the standard institutional cooling protocol.

Clinical assessments and clinically relevant adverse events will be documented from the time the patient is enrolled to the study until the first of the following two events occur: death or MRI scan.

Patients that regain consciousness following ROSC and prior to hospital transport will be excluded. Patient's still unconscious in the emergency room are admitted to ICU and therapeutic cooling is continued for 24 to 36 hours. The MRI scan will take place within 16 hours after rewarming. After that the sedation is stopped and patient extubated if possible. The study is finished at that point and normal patient care continues.

The study continues until 10 patients with MRI scan are enrolled in Tampere University Hospital (TAUH).


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date April 1, 2016
Est. primary completion date April 1, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Ventricular fibrillation or non-perfusive ventricular tachycardia as initial cardiac rhythm.

2. The 1st attempt at resuscitation by emergency medical personnel must appear within 15 minutes after the collapse.

3. The cause for collapse should be considered primary as cardiogenic and the return of spontaneous circulation (ROSC) should have been gained in 45 minutes after the collapse.

4. Patient should be still unconscious in the emergency room.

5. Age: 18 - 80 years

6. Obtained consent after arrival to the hospital, and before MRI scan.

Exclusion Criteria:

7. Hypothermia (< 30°C core temperature)

8. Arrival of EMS after 15 minutes from collapse

9. Unconsciousness before cardiac arrest (cerebral trauma, spontaneous cerebral haemorrhages, intoxications etc.)

10. Terminal phase of a chronic disease, or known limitations in therapy and Do Not Resuscitate-order or known pre-arrest Cerebral Performance Category 3 or 4

11. Factors making participation in follow-up unlikely

12. Factors making the RhinoChill cooling contraindicated: patients with known contraindications to hypothermia (Raynaud's disease, Cryoglobulinemia, Sickle Cell disease), have specific temperature-sensitive pathologies (e.g., serum cold agglutinins, Buerger's disease), intranasal obstruction, or known skull base fracture.

13. Pregnancy

14. Coagulopathy

15. Response to verbal commands after the return of spontaneous circulation (ROSC)

16. Systolic arterial pressure < 80 mmHg or mean arterial pressure < 60 mmHg for over 30 min period after ROSC

17. Evidence of hypoxemia (arterial oxygen saturation < 85%) for > 15 minutes after ROSC

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Finland Tampere University hospital Tampere

Sponsors (4)

Lead Sponsor Collaborator
Tampere University Hospital BeneChill, Inc, Helsinki University Central Hospital, Turku University Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Other time to reach a target temperature (=36/33 Celsius) 0-12hours after cardiac arrest
Primary the presence and pattern of white matter and gray matter degeneration and volumetric changes of the gray matter, white matter, and cerebro-spinal fluid spaces in MRI 36-49 hours after cardiac arrest
Secondary the total survival at 90 days 90 days after cardiac arrest
See also
  Status Clinical Trial Phase
Recruiting NCT06048068 - Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events N/A
Recruiting NCT05558228 - Accuracy of Doppler Ultrasound Versus Manual Palpation of Pulse in Cardiac Arrest
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Completed NCT04619498 - Effectiveness of an Interactive Cognitive Support Tablet App to Improve the Management of Pediatric Cardiac Arrest N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT02352350 - Lactate in Cardiac Arrest N/A
Completed NCT03024021 - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed NCT02247947 - Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome
Completed NCT02275234 - Care After Resuscitation
Completed NCT01944605 - Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest N/A
Completed NCT01936597 - Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage N/A
Completed NCT01972087 - Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest N/A
Active, not recruiting NCT01239420 - Norwegian Cardio-Respiratory Arrest Study
Completed NCT00878644 - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial Phase 3
Completed NCT00880087 - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial N/A
Completed NCT01191736 - Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice N/A
Completed NCT00729794 - Vasopressin, Epinephrine, and Steroids for Cardiac Arrest Phase 3
Recruiting NCT00441753 - Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest N/A
Completed NCT00347477 - Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest Phase 3